Meningococcal B vaccine shows no effect on gonorrhea rates in MSM, RCT finds

The New England Journal of Medicine has published the results of the world’s largest randomized controlled trial (RCT) evaluating the potential of the meningococcal B vaccine (4CMenB) to prevent gonorrhea among men who have sex with men (MSM) at high risk of infection. The GoGoVax study, which enrolled thousands of participants across multiple countries, found that the vaccine had no statistically significant effect on the incidence of gonorrhea compared with placebo.

These findings contrast with earlier observational studies that had suggested a protective benefit of 4CMenB against gonorrhea, a result that had prompted several countries to adopt vaccination programs targeting MSM. The GoGoVax trial’s rigorous design and large sample size provide the most definitive evidence to date, indicating that the meningococcal B vaccine does not confer cross‑protection against Neisseria gonorrhoeae in this population.

Public health authorities will need to reassess the role of 4CMenB in gonorrhea prevention strategies, focusing instead on proven interventions such as regular screening, condom use, and treatment of asymptomatic carriers. The study underscores the importance of large, randomized trials in validating vaccine efficacy claims that arise from observational data.